World Renowned International Psychedelics Experts Join Clarion Clinics Advisory Board
MELBOURNE, Australia, May 30, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’), a pharmaceutical company developing proprietary drugs which use cannabis as an ingredient for unmet medical needs, psychedelic-assisted psychotherapy protocols, and an operator of psychedelic-assisted psychotherapy clinics, is pleased to announce that three of the world’s top psychedelic therapy and science experts have joined the Advisory Board of Clarion Clinics Group.
- Three world-leading clinical psychedelics experts join Clarion Clinics Advisory Board.
- The company is delighted to announce that, in addition to the most experienced psychedelics professionals in Australia taking key executive roles and directorships in the Clarion Clinics Group, three of the world’s most experienced and leading clinical psychedelic experts have joined its Advisory Board.
- Andrea serves as the Medical Director of the OVID Clinics in Berlin, and is a co-founder and advisory board member of the MIND Foundation.
- I’m grateful for their trust and support.”
Peter Widdows, Incannex Director, said: “I’m delighted and honoured that such esteemed professionals have decided to join the Clarion Clinics team.